Amgen wins approval for cholesterol drug Repatha | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 28 August, 2015 by The TZ Newswire Staff

Amgen wins approval for cholesterol drug Repatha

Amgen has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol.

See also
- Next Article China’s Stock Rout to Resume as Intervention Ends, Says BofA
- Previous Article Market Snapshot: U.S. stocks set to fall as volatile week leaves investors wary
Editorial Calender

August 2015

M T W T F S S

1 2

3 4 5 6 7 8 9

10 11 12 13 14 15 16

17 18 19 20 21 22 23

24 25 26 27 28 29 30

31

« Jul Sep »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar